Regeneron gets $10M milestone on Phase III results

Bayer and Regeneron Pharmaceuticals announced positive Phase III results for the first of two studies of VEGF Trap-Eye (aflibercept ophthalmic solution) for patients with macular edema due to central retinal vein occlusion. Regeneron get a $10 million milestone payment from Bayer because the trial met its primary endpoint. Release

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.